Why the study?
Does the Alere Heart Check capillary BNP test perform comparably to standard plasma BNP measurement in patients with stable chronic heart failure?
Does the Alere Heart Check capillary BNP test perform comparably to standard plasma BNP measurement in patients with stable chronic heart failure?
The Alere Heart Check point-of-care capillary BNP test provides comparable clinical performance to standard plasma BNP testing for assessing dyspnea in stable heart failure patients, despite lower precision.
Answers are grounded in this paper and cite their sources.
May support capillary BNP for dyspnea assessment in stable HF; leaves open prospective validation and precision at high levels.
AIM: We have evaluated here the clinical and analytical performance of the Alere™ Heart Check (AHC) test, a rapid point-of-care immunoassay designed for the measurement of BNP from fresh capillary whole blood. PATIENTS & METHODS: One-hundred-and-sixty-three patients with stable chronic heart failure followed at the cardiac rehabilitation were submitted to simultaneous capillary (AHC) and plasma (Abbott architect system) BNP measurements. RESULTS: Both methods showed a good correlation, although the values diverged when BNP was higher than 2000 pg/ml. Despite a relatively poor precision of AHC, however, both methods showed the same performances to assess patients' dyspnea and equivalent sensitivity, specificity, negative and positive predicting values. CONCLUSION: AHC BNP test is a good POC for the management of heart failure despite a relatively poor precision.
No takes yet. Share an insight, caveat, or question.
Monfort et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: